PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22633931-0	2012	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.	vandetanib	60-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-156	
22633931-0	2012	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.	vandetanib	60-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-162	
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	vandetanib	73-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-154	
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	vandetanib	73-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	218-222	
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	vandetanib	242-252	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-154	
22633931-4	2012	In vitro studies suggested that vandetanib is a high affinity substrate of Bcrp1 but is not transported by P-gp.	vandetanib	32-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80	
22633931-5	2012	Interestingly, in vivo brain distribution studies in FVB wild type mice indicated that vandetanib penetration into the brain is restricted by both Bcrp1 and P-gp mediated active efflux at the blood brain barrier (BBB).	vandetanib	87-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-152	
22633931-6	2012	Co-administration of elacridar, a dual P-gp/BCRP inhibitor increased the brain to plasma concentration ratio of vandetanib upto 5 fold.	vandetanib	112-122	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48